Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024)
Artiva Biotherapeutics (ARTV) reported Total Non-Current Liabilities of $22.9 million for Q4 2024, down 10.73% year-over-year from $25.6 million in Q1 2024, and down 6.77% quarter-over-quarter from $24.5 million in Q3 2024.
Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 2 years of Total Non-Current Liabilities data on file, last reported at $22.9 million in Q4 2024.
- Total Non-Current Liabilities for Q4 2024 came in at $22.9 million, down 10.73% year-over-year; the trailing twelve-month figure through Dec 2024 was $22.9 million (down 10.73% YoY), and the FY2024 annual result was $22.9 million, down 10.73% from the prior year.
- Total Non-Current Liabilities eased to $22.9 million in Q4 2024 per ARTV's latest filing, from $24.5 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $50.5 million in Q2 2024 and troughed at $22.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Artiva Biotherapeutics | 241.85 Mn | 241.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 22.87 Mn |
| Sep 30, 2024 | 24.53 Mn |
| Jun 30, 2024 | 50.52 Mn |
| Dec 31, 2023 | 25.62 Mn |